The ARTEMIS-001 phase 1 trial aimed to present updated efficacy and safety results of HS-20093 in ES-SCLC from dose-escalation and dose-expansion phases. Efficacy endpoints were ORR, DCR, DoR, PFS, and OS. HS-20093 showed encouraging antitumor activity with manageable safety in patients with previously treated ES-SCLC. The ARTEMIS-001 study is a multicenter, open-label Phase […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Major histocompatibility complex class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
